Agios Pharmaceuticals, Inc.(AGIO)

$35.40—

Chart

Agios Pharmaceuticals, Inc.(AGIO)

NASDAQ

$35.40—

Chart Studio

AGIO(AGIO)

AGIO

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-1.21

Oct 29, 2026 · Reports before open

Revenue Estimate

$54M

FY2030E EPS$0.20

Analyst Sentiment

Wall St. Consensus

Buy

27 analysts·High coverage

Score

22 Buy (81%)5 Hold (19%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

2281%

Hold

519%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$32.00

-9.6%

Consensus

$41.00

+15.9%

Bull

$55.00

+55.4%

12-Month Target Range27 analysts

$32.00$41.00$55.00

Current $35.39Consensus

Current Price

$35.39

Upside to Consensus

$5.61

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+88.80%

EPS—

FY2028

Rev+41.30%

EPS—

FY2029

Rev+23.66%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$175M	$330M	$467M	$577M	$727M
Low	$131M	$248M	$294M	$395M	$498M
High	$252M	$422M	$684M	$760M	$957M
EBITDA Avg	$-35M	$-66M	$-93M	$-115M	$-145M
Low	$-50M	$-84M	$-137M	$-152M	$-191M
High	$-26M	$-50M	$-59M	$-79M	$-100M
EBIT Avg	$-35M	$-66M	$-93M	$-115M	$-145M
Low	$-50M	$-84M	$-137M	$-152M	$-191M
High	$-26M	$-50M	$-59M	$-79M	$-100M
Net Income Avg	$-356M	$-266M	$-188M	$-83M	$12M
Low	$-402M	$-305M	$-212M	$-117M	$7M
High	$-298M	$-187M	$-98M	$-49M	$17M
EPS Avg	$-5.86	$-4.02	$-2.59	$-1.43	$0.20
Low	$-6.93	$-5.26	$-3.65	$-2.03	$0.12
High	$-5.15	$-3.23	$-1.69	$-0.85	$0.29
Analysts (Rev / EPS)	7 / 7	7 / 8	7 / 5	3 / 1	5 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027
Revenue Avg	$51M	$60M	$66M	$85M
Low	$37M	$41M	$53M	$68M
High	$78M	$94M	$92M	$118M
EBITDA Avg	$-10M	$-12M	$-13M	$-17M
Low	$-16M	$-19M	$-18M	$-24M
High	$-7M	$-8M	$-11M	$-14M
EBIT Avg	$-10M	$-12M	$-13M	$-17M
Low	$-16M	$-19M	$-18M	$-24M
High	$-7M	$-8M	$-11M	$-14M
Net Income Avg	$-76M	$-70M	$-68M	$-58M
Low	$-95M	$-77M	$-102M	$-87M
High	$-59M	$-56M	$-50M	$-43M
EPS Avg	$-1.28	$-1.17	$-1.14	$-0.98
Low	$-1.59	$-1.30	$-1.71	$-1.47
High	$-1.00	$-0.94	$-0.84	$-0.72
Analysts (Rev / EPS)	6 / 6	6 / 6	3 / 2	3 / 2

Earnings Surprises

Recent Analyst Actions

Jul 30, 2026H.C. Wainwright

Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright

Target:$55.00

+67.0%from $32.92

Jul 21, 2026H.C. Wainwright

Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright

Target:$52.00

+37.7%from $37.77

Jul 7, 2026Truist Financial

Agios Pharmaceuticals price target raised to $41 from $36 at Truist

Target:$41.00

-2.5%from $42.07

Jul 7, 2026RBC Capital

Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital

Target:$32.00

-14.4%from $37.39

Jun 15, 2026H.C. Wainwright

Agios Pharma (AGIO) PT Raised to $54 at H.C. Wainwright

Target:$54.00

+83.3%from $29.46

Apr 30, 2026Truist Financial

Agios Pharmaceuticals price target lowered to $36 from $39 at Truist

Target:$36.00

+28.3%from $28.05

Apr 20, 2026H.C. Wainwright

H.C. Wainwright cuts Agios target on smaller market post Novo data

Target:$50.00

+85.7%from $26.93

Feb 12, 2026Truist Financial

Agios Pharma (AGIO) PT Raised to $39 at Truist Securities

Target:$39.00

+37.3%from $28.41

Dec 26, 2025Leerink Partners

Agios Pharmaceuticals price target raised to $40 from $34 at Leerink

Target:$40.00

+37.1%from $29.17

Dec 24, 2025H.C. Wainwright

Agios Pharmaceuticals price target raised to $62 from $48 at H.C. Wainwright

Target:$62.00

+112.5%from $29.17

Dec 24, 2025Truist Financial

Agios Pharmaceuticals price target raised to $38 from $32 at Truist

Target:$38.00

+30.3%from $29.17

Nov 24, 2025Truist Financial

Agios Pharmaceuticals initiated with a Buy at Truist

Target:$32.00

+26.8%from $25.24

Nov 20, 2025Goldman Sachs

Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs

Target:$25.00

-2.2%from $25.55

Nov 20, 2025Leerink Partners

Leerink upgrades Agios to Outperform after 51% pullback

Target:$34.00

+52.2%from $22.34

Oct 20, 2025H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO)

Target:$56.00

+32.3%from $42.33

May 2, 2025Scotiabank

Agios Pharmaceuticals price target lowered to $71 from $74 at Scotiabank

Target:$71.00

+135.9%from $30.10

Oct 31, 2024Raymond James

Raymond James Reiterates Outperform Rating on Agios Pharma (AGIO)

Target:$51.00

+14.8%from $44.43

Sep 27, 2024Leerink Partners

Leerink Partners Downgrades Agios Pharma (AGIO) to Market Perform

Target:$56.00

+22.8%from $45.61

Sep 10, 2024Raymond James

Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)

Target:$56.00

+27.1%from $44.05

Jun 17, 2024Raymond James

Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)

Target:$55.00

+26.7%from $43.42

Jun 3, 2024RBC Capital

Agios Pharmaceuticals price target raised to $53 from $44 at RBC Capital

Target:$53.00

+19.7%from $44.26

May 28, 2024Raymond James

Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)

Target:$45.00

+17.2%from $38.39

Feb 3, 2023Piper Sandler

Piper Sandler Initiates Coverage On Agios Pharmaceuticals with Overweight Rating, Announces Price Target of $41

Target:$41.00

+35.9%from $30.18

Dec 1, 2022J.P. Morgan

JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $33

Target:$33.00

+12.0%from $29.46

Nov 17, 2022Goldman Sachs

Goldman Sachs Upgrades Agios Pharmaceuticals to Neutral, Raises Price Target to $32

Target:$32.00

+18.0%from $27.13

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance